Clinical Trials
16 trialsNCT07605949 2026-05-27
RAVEN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07581002 2026-05-12
REVIVAL
AbbVie
Phase 2/3 Not yet recruiting
NCT07548983 2026-04-23
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
OHSU Knight Cancer Institute
Phase 1 Not yet recruiting
NCT05554419 2026-04-13
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07469046 2026-04-13
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3 Not yet recruiting
NCT07507825 2026-04-02
VHAG
First People's Hospital of Hangzhou
Phase 2 Not yet recruiting
NCT07407140 2026-03-25
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT07486479 2026-03-20
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University
Phase 3 Not yet recruiting
NCT07486726 2026-03-20
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
Phase 1/2 Not yet recruiting
NCT07478991 2026-03-18
VENP-A-QUI
PETHEMA Foundation
Phase 3 Not yet recruiting
NCT07387354 2026-03-16
MDS
Thomas Jefferson University
Phase 1/2 Not yet recruiting
NCT07471841 2026-03-13
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT07463768 2026-03-11
MIVONU
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT07060001 2026-03-06
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
Phase 2 Not yet recruiting
NCT07255872 2026-03-05
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT07439211 2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting